Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762979 | 0.81 | CA2 (0.54) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1105200 | 0.81 | CA2 (0.65) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL9041969 | 0.80 | CA1 (0.46) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7558142 | 0.78 | CA2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL6046339 | 0.78 | CA2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL12760595 | 0.74 | CA2 (0.59) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL27495668 | 0.74 | CA2 (0.64) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL28267397 | 0.73 | CA2 (0.55) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL9019311 | 0.72 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1131010 | 0.72 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6048975-A | USE OF DANSYLETHOXYCARBONYL GROUP AS BASE-LABILE 5'-HYDROXYL PROTECTIVE GROUP; EASE OF DETECTION AND EASE OF ELIMINATION WITH BY-PRODUCT INHIBITION FOR HIGH YIELD SYNTHESIS IN VERY SMALL QUANTITIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-04-11 | — | — | US | claimed |
| US-5945524-A | NUCLEOSIDE WITH DANSYLETHOXYCARBONYL GROUP AS BASE-LABILE 5'-HYDROXYL PROTECTIVE GROUP; FOR EFFICIENT SYNTHESIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | claimed |
| EP-0475443-B1 | Chemical synthesis of oligonucleotides | HOECHST AG (DE) | 1994-10-19 | — | — | EP | claimed |
| JP-5320122-A | — | — | None | — | — | JP | disclosed |
| EP-2955171-A1 | MANUFACTURE PROCESS OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID | Novartis AG (CH) | 2015-12-16 | — | — | EP | disclosed |
| EP-1838664-B1 | MANUFACTURE PROCESS OF N-SUBSTITUTED SALICYLAMIDES | NOVARTIS AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-8461385-B2 | Manufacture process of organic compounds | NOVARTIS AG (CH) | 2013-06-11 | — | — | US | disclosed |
| EP-1212338-B1 | Nucleoside derivatives with photolabile protective groups | DEUTSCHES KREBSFORSCH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-8314071-B2 | Bioactive molecules from co-cultivation of microbes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8026383-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives | BASF SE (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | CIBA SPECIALTY CHEMICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-5945524-A | NUCLEOSIDE WITH DANSYLETHOXYCARBONYL GROUP AS BASE-LABILE 5'-HYDROXYL PROTECTIVE GROUP; FOR EFFICIENT SYNTHESIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5631362-A | FORMING DNA AND RNA BY POLYCONDENSATION OF MONONUCLEOTIDES WITH PROTECTIVE SULFONYLALKYL DIMETHYLAMINONAPHTHALENE GROUPS FOR ALKOXY FURAN GROUPS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| US-5631362-A | FORMING DNA AND RNA BY POLYCONDENSATION OF MONONUCLEOTIDES WITH PROTECTIVE SULFONYLALKYL DIMETHYLAMINONAPHTHALENE GROUPS FOR ALKOXY FURAN GROUPS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0475443-B1 | Chemical synthesis of oligonucleotides | HOECHST AG (DE) | 1994-10-19 | — | — | EP | disclosed |
| JP-H05320122-A | CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDE | HOECHST AG | 1993-12-03 | — | — | JP | disclosed |
| EP-0475443-A2 | Chemical synthesis of oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | disclosed |
| EP-0475443-A2 | Chemical synthesis of oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | HMGCR, SREBF1, LCAT | CA2 910/4885CYP1A2 200/4885CYP2C19 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.